The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN
Open accessAbstract
Toll-like receptors are important in the activation of innate immunity, and CD40 is a molecule critical for many T and B cell responses. Whereas agonists for either pathway have been used as vaccine adjuvants, we show that a combination of Toll-like receptor (TLR)7 and CD40 agonists synergize to stimulate CD8+ T cell responses 10–20-fold greater than the use of either agonist alone. Antigen-specific CD8+ T cells elicited from combination CD40/TLR7 treatment demonstrated both lytic activities and interferon (IFN)γ production and an enhanced secondary response to antigenic challenge. Agonists for TLRs 2/6, 3, 4, and 9 also synergized with CD40 stimulation, demonstrating that synergy with the CD40 pathway is a property of TLR-derived stimuli in general. The CD8+ T cell expansion induced by CD40/TLR7 triggering was independent of CD4+ T cells, IFNγ, and IL-12 but dependent on B7-mediated costimulation and surprisingly on type I IFN. These studies provide the rational basis for the use of TLR and CD40 agonists together as essential adjuvants to optimize vaccines designed to elicit protective or therapeutic immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80119-3 · Cited by 3,362
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,092
Unresponsiveness of MyD88-Deficient Mice to Endotoxin
Kawai, T., Adachi, O., Ogawa, T., Takeda, K., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80086-2 · Cited by 2,076
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041
Activation of human dendritic cells through CD40 cross-linking.
Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I., & Banchereau, J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1263 · Cited by 1,317
Cited by
IRF-7 is the master regulator of type-I interferon-dependent immune responses
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N., Ohba, Y., Takaoka, A., Yoshida, N., et al. (2005) · Nature · doi:10.1038/nature03464 · Cited by 2,245
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
VISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486
Self-citationHailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M. A., Huang, X.-F., Dorta-Estremera, S. M., Greeley, N. R., Nitti, G., Peng, W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3105 · Cited by 457
Nancy, P., Tagliani, E., Tay, C.-S., Asp, P., Levy, D. E., & Erlebacher, A. (2012) · Science · doi:10.1126/science.1220030 · Cited by 429
Haluszczak, C., Akue, A. D., Hamilton, S. E., Johnson, L. D. S., Pujanauski, L., Teodorovic, L., Jameson, S. C., & Kedl, R. M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081829 · Cited by 377
Self-citationRegulation of the type I IFN induction: a current view
Honda, K., Yanai, H., Takaoka, A., & Taniguchi, T. (2005) · International Immunology · doi:10.1093/intimm/dxh318 · Cited by 348
TLR agonists: our best frenemy in cancer immunotherapy
Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339
Memory T cells: strategies for optimizing tumor immunotherapy
Liu, Q., Sun, Z., & Chen, L. (2020) · Protein & Cell · doi:10.1007/s13238-020-00707-9 · Cited by 326
Soares, H., Waechter, H., Glaichenhaus, N., Mougneau, E., Yagita, H., Mizenina, O., Dudziak, D., Nussenzweig, M. C., & Steinman, R. M. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070176 · Cited by 316
CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282
The Immune Revolution: A Case for Priming, Not Checkpoint
Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 293
BLyS and APRIL in rheumatoid arthritis
Seyler, T. M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25265 · Cited by 266
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
Vasilakos, J. P., & Tomai, M. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811208 · Cited by 254
Self-citationSosinowski, T., White, J. T., Cross, E. W., Haluszczak, C., Marrack, P., Gapin, L., & Kedl, R. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203149 · Cited by 149
Self-citationTamburini, B. A., Burchill, M. A., & Kedl, R. M. (2014) · Nature Communications · doi:10.1038/ncomms4989 · Cited by 153
Self-citationPeptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Harada, K., Isse, K., & Nakanuma, Y. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.023507 · Cited by 98
Toll-like receptor agonists: a patent review (2011 - 2013)
Hussein, W. M., Liu, T.-Y., Skwarczynski, M., & Toth, I. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.880691 · Cited by 68
Wells, J. W., Cowled, C. J., Farzaneh, F., & Noble, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3422 · Cited by 53
Molecular tracking devices quantify antigen distribution and archiving in the murine lymph node
Walsh, S. M., Sheridan, R. M., Lucas, E. D., Doan, T. A., Ware, B. C., Schafer, J., Fu, R., Burchill, M. A., Hesselberth, J. R., & Tamburini, B. A. J. (2021) · eLife · doi:10.7554/elife.62781 · Cited by 28
Metadata
- Authors
- Ahonen, C. L., Doxsee, C. L., McGurran, S. M., Riter, T. R., Wade, W. F., Barth, R. J., Vasilakos, J. P., Noelle, R. J., & Kedl, R. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-03-08
- Volume
- 199
- Issue
- 6
- Pages
- 775-784
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2131811425
- Cited by
- 362
- References
- 59
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.